Skip to content

FMT for patients withIBD and the impact of variaty in donor’ microbiota on the efficacy

Usefulness of FMT in IBD patients and the impact of donor microbiota variety on efficacy of treatment

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-16009382
Enrollment
Unknown
Registered
2016-10-12
Start date
2017-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

inflammatory bowel disease

Interventions

1:one donor feces
2:two to three donor feces

Sponsors

Shanghai Renji Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Eligible patients were 18 years or older with active UC defined as a Mayo Clinic score16 4 with an endoscopic Mayo Clinic score 1. Concomitant treatments for UC, such as mesalamine, glucocorticoids, immunosuppressive therapy (eg,azathioprine), or tumor necrosis factor antagonists were permitted, provided these had been used at a stable dose for at least 12 weeks (4 weeks for glucocorticoids) and disease remained active.

Exclusion criteria

Exclusion criteria: Patients were excluded if they had taken antibiotics or probiotics in the last 30 days, had concomitant C difficile infection or another enteric pathogen, had a disease severity that required hospitalization, were pregnant, or were unable to give informed consent.

Design outcomes

Primary

MeasureTime frame
Mayo score;Endoscopic Mayo score;

Countries

China

Contacts

Public ContactZhihua Ran

Shanghai Renji Hospital

zhihuaran@vip.163.com+86 13801868827

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026